Clinical trials
Phase 2 Iron Overload trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
35 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2003 | 4 |
| 2004 | 1 |
| 2005 | 3 |
| 2006 | 1 |
| 2007 | 5 |
| 2008 | 2 |
| 2010 | 3 |
| 2011 | 1 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2022 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 23 |
| Terminated | 4 |
| Withdrawn | 3 |
| Active, not recruiting | 2 |
| Recruiting | 2 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 12 |
| Shire | 3 |
| Hangzhou Zede Pharma-Tech Co., Ltd. | 2 |
| Abfero Pharmaceuticals, Inc | 1 |
| Andrea Kew | 1 |
| ApoPharma | 1 |
| CSL Behring | 1 |
| Case Western Reserve University | 1 |
| City of Hope Medical Center | 1 |
| Elliott Vichinsky | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Iron Overload | 35 |
| Thalassemia | 9 |
| beta-Thalassemia | 9 |
| Hemochromatosis | 7 |
| Myelodysplastic Syndromes | 6 |
| Anemia, Sickle Cell | 5 |
| Anemia | 4 |
| Anemia, Diamond-Blackfan | 2 |
| Breast Neoplasms | 2 |
| Hematologic Diseases | 2 |
Trials
Showing 76 to 35 of 35. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.